To evaluate the in-vivo safety and efficacy of Skin care formulation in terms of Reduction in Acne and Sebum Reduction on healthy female subjects - Nil

Onesto Labs Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

研究概览

暂无简介。

•1.Indian female subjects.
•2. Healthy Subjects
•3.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)
•4.Having oily to mixed oily skin type.
•5.Having mild to moderate acne.

•1. Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
•2. Having refused to give her/his assent by not signing the consent form
•3. Taking part in another study liable to interfere with this study
•4. Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)
•5. Having a progressive asthma (either under treatment or last fit in the last 2 years)
•6. Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis)
•7. Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
•8. Being epileptic.
•9. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
•10. Having cutaneous hypersensitivity.
•11. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
•12. Having undergone a surgery requiring a general anesthetic of more than one hour in the past 6

发起方

Onesto Labs Pvt. Ltd.